VolitionRx Limited’s (NYSEMKT:VNRX): VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. On 31 December 2019, the US$128m market-cap posted a loss of -US$16.1m for its most recent financial year. As path to profitability is the topic on VNRX’s investors mind, I’ve decided to gauge market sentiment. Below I will provide a high-level summary of the industry analysts’ expectations for VNRX.
VNRX is bordering on breakeven, according to the 3 Medical Equipment analysts. They anticipate the company to incur a final loss in 2021, before generating positive profits of US$12m in 2022. VNRX is therefore projected to breakeven around 2 years from now. What